Who are Ultra-Long GnRH Agonists's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Gonapeptyl®, Dual Trigger, Cetrorelix and Leuprolide, Antagonist GnRH Cetrotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ultra-long-gnrh-agonists.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ultra-Long GnRH Agonists — Competitive Intelligence Brief

Ultra-Long GnRH Agonists (Ultra-Long GnRH Agonists) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology; Endocrinology.

marketed GnRH agonist GnRH receptor Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Ultra-Long GnRH Agonists (Ultra-Long GnRH Agonists) — University of Palermo. Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ultra-Long GnRH Agonists TARGET	Ultra-Long GnRH Agonists	University of Palermo	marketed	GnRH agonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Gonapeptyl®	Gonapeptyl®	University Hospital, Ghent	marketed	GnRH agonist	GnRH receptor
Dual Trigger	Dual Trigger	Weill Medical College of Cornell University	marketed	Reproductive hormone protocol	GnRH receptor and LH receptor
Cetrorelix and Leuprolide	Cetrorelix and Leuprolide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist and GnRH agonist combination	GnRH receptor
Antagonist GnRH Cetrotide	Antagonist GnRH Cetrotide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist class)

Takeda · 4 drugs in this class
Abbott · 3 drugs in this class
Ipsen · 3 drugs in this class
Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
University of Pisa · 2 drugs in this class
Chong Qing Reproducive and Genetic Institute · 1 drug in this class
Chesapeake Urology Research Associates · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Enteris BioPharma Inc. · 1 drug in this class
Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ultra-Long GnRH Agonists — Competitive Intelligence Brief. https://druglandscape.com/ci/ultra-long-gnrh-agonists. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab